The Necker–Enfants Malades Hospital is a French teaching hospital in the 15th arrondissement of Paris. It is a hospital of the Assistance Publique – Hôpitaux de Paris group and is affiliated to the University of Paris Descartes.

There are 600 beds in Hôpital Necker-Enfants Malades.

During the past decade, Hôpital Necker-Enfants Malades conducted 479 clinical trials. In the 10-year time frame, 479 clinical trials started and 91 clinical trials were completed, i.e. on average, 19% percent of trials that started reached the finish line to date. In the past 5 years, 230 clinical trials started and 67 clinical trials were completed. i.e. 29.1% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Hôpital Necker-Enfants Malades" #1 sponsor was "Assistance Publique - Hôpitaux de Paris" with 202 trials, followed by "The Lymphoma Academic Research Organisation" with 24 trials sponsored, "Nantes University Hospital" with 17 trials sponsored, "ANRS, Emerging Infectious Diseases" with 16 trials sponsored and "Hospices Civils de Lyon" with 16 trials sponsored. Other sponsors include 422 different institutions and companies that sponsored additional 188 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Hôpital Necker-Enfants Malades" #1 collaborator was "Ministry of Health, France" with 10 trials as a collaborator, "Institut National de la Santé Et de la Recherche Médicale, France" with 8 trials as a collaborator, "Novartis" with 8 trials as a collaborator, "Roche Pharma AG" with 8 trials as a collaborator and "Assistance Publique - Hôpitaux de Paris" with 5 trials as a collaborator. Other collaborators include 268 different institutions and companies that were collaborators in the rest 214 trials.

According to Clinical.Site data, the most researched conditions in "Hôpital Necker-Enfants Malades" are "Cystic Fibrosis" (33 trials), "Multiple Myeloma" (15 trials), "Kidney Transplantation" (12 trials), "HIV-1 Infection" (9 trials) and "Hemophilia A" (9 trials). Many other conditions were trialed in "Hôpital Necker-Enfants Malades" in a lesser frequency.

Most popular intervention types in "Hôpital Necker-Enfants Malades" are "Drug" (341 trials), "Other" (157 trials), "Biological" (63 trials), "Procedure" (41 trials) and "Device" (24 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (66 trials), "Rituximab" (12 trials), "Ataluren" (9 trials), "Dexamethasone" (8 trials) and "IVA" (8 trials). Other intervention names were less common.

The vast majority of trials in "Hôpital Necker-Enfants Malades" are 635 trials for "All" genders, 35 trials for "Female" genders and 27 trials for "Male" genders.

Currently, there are 225 active trials in "Hôpital Necker-Enfants Malades". 15 are not yet recruiting, 147 are recruiting, 60 are Active, not recruiting, and 3 are Enrolling by invitation. In total, there were 355 completed trials in Hôpital Necker-Enfants Malades, 1 suspended trials, and 47 terminated clinical trials to date.

Out of the total trials that were conducted in Hôpital Necker-Enfants Malades, 33 "Phase 1" clinical trials were conducted, 146 "Phase 2" clinical trials and 199 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 25 trials, and there were also 137 trials that are defined as “Not Applicable".